Episode Details
Back to Episodes
Daily Roundup | GSK Ends Alector Neuroscience Bet: What the $2.2B Unwind Signals
Published 1 week, 6 days ago
Description
GSK walked away from its $2.2 billion Alector alliance, ending its neuroscience re-entry as clinical setbacks piled up. Plus: the FDA resumes releasing rejection letters with fourteen new CRLs, Hengrui and Elevar's PD-1 liver cancer combo is rejected a third time, Sanofi's subcutaneous Sarclisa wins approval, Pfizer/Astellas and Merck expand Padcev-Keytruda in muscle-invasive bladder cancer, Vera Therapeutics scores an IgA nephropathy nod against Otsuka, AstraZeneca and Ionis miss a Phase 3 heart trial, Apnimed files to IPO amid its sleep apnea review, and Moderna sinks in a broad biotech selloff.
Visit us at thepharmacloseout.com.